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Pandemic (H1N1) 2009 infl uenza spread through the 
Northern Territory, Australia, during June–August 2009. We 
performed 2 cross-sectional serologic surveys on specimens 
from Northern Territory residents, with 445 specimens 
obtained prepandemic and 1,689 specimens postpandemic. 
Antibody titers were determined by hemagglutination 
inhibition against reference virus A/California/7/2009 on 
serum samples collected opportunistically from outpatients. 
All specimens had data for patients’ gender, age, and 
address, with patients’ indigenous status determined for 
94.1%. Protective immunity (titer >40) was present in 7.6% 
(95% confi dence interval [CI] 5.2%–10.1%) of prepandemic 
specimens and 19.5% (95% CI 17.6%–21.4%) of 
postpandemic specimens, giving a population-standardized 
attack rate of 14.9% (95% CI 11.0%–18.9%). Prepandemic 
proportion of immune persons was greater with increasing 
age but did not differ by other demographic characteristics. 
Postpandemic proportion of immune persons was greater in 
younger groups and around double in indigenous persons. 
Postpandemic proportion immune was geographically 
heterogeneous, particularly among remote-living and 
indigenous groups. 
Understanding the epidemiology of pandemic infl uenza is essential in directing public health responses, not 
only to the current pandemic, but also for recurrent waves of 
the same virus and future infl uenza pandemics. Knowledge 
of the distribution of protective immunity enables prediction 
of groups susceptible to reemergence of the virus and thus 
helps to improve effi cacy of vaccine programs. Infl uenza 
has uneven effects across demographic and geographic 
groups, which may contribute to the increases in illness and 
death sometimes seen with subsequent waves (1,2). There 
is an emerging understanding of the effects of the outbreak 
of pandemic (H1N1) 2009 on indigenous populations, but 
little is known of the virus’s effect on remote and socio-
economically disadvantaged groups.
Direct serologic measures of population immunity 
are useful in assessing the effect of pandemic infl uenza, 
as case or surveillance-based measures of incidence of 
infection are dependent on recognition of symptoms, use 
of health services, and subsequent testing (3). In remote 
and ethnically diverse populations, the differential effect of 
these factors may be particularly marked.
The Northern Territory (NT) is a jurisdiction unique 
for its large area of 1.35 million km2 (twice that of Texas) 
relative to its population of 225,000, of whom 30% are 
indigenous. The climate ranges from desert and semi-arid 
in central Australia to tropical in the northern “Top End” 
where the capital, Darwin, is located. There are also several 
smaller urban centers and many small, remote indigenous 
communities of 300–2,000 that may be >2 h fl ight from 
the nearest hospital. Indigenous Australians of the NT 
have considerably poorer health than the nonindigenous 
majority, with a life-expectancy gap of 15–20 years (4).
Following recognition of the pandemic (H1N1) 2009 
virus in North America in April 2009, Australia experienced 
a single pandemic wave leading into the Southern 
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Hemisphere winter (5). Despite enacting carefully prepared 
nationwide public health measures to delay viral entry and 
spread, widespread infection followed (6,7). Australia’s 
fi rst case was reported on May 8, with the fi rst case in the 
NT reported on June 2 and the fi rst NT death occurring 
July 9 (8). Australia moved to the “protect” phase of its 
pandemic response on June 17 in an effort to limit illness 
and death from the virus (9), with notifi cations peaking 
nationwide and in the NT in July (10).
We undertook serosurveys using opportunistically 
collected outpatient serum specimens from persons across 
the NT to estimate levels of pre-existing immunity and 
differential attack rates among demographic groups. Our 
study included a large proportion of remote-living persons, 
including Aboriginal and Torres Strait Islanders, enabling 
assessment of the differential effect of infl uenza upon these 
populations.
Methods
Specimens
Specimens were obtained from Western Diagnostic 
Pathology (Myaree, Western Australia, Australia), which 
provides outpatient pathology services covering most of 
the NT. Specimens were eligible for inclusion regardless of 
indication for testing, provided identifying information was 
complete and address was within the NT. We accepted only 
serum tubes with a residual volume >0.5 mL and obtained 
specimens before routine discarding. Baseline specimens 
were selected during January–May and all postpandemic 
specimens from September 2009.
Background Information
Data obtained for each specimen consisted of date 
of collection, patient’s age in years at collection, gender, 
suburb/community of address, and a unique study 
identifi er. Identifying data (name and date of birth) were 
transferred directly from the laboratory to the Information 
Services Division of the NT Department of Health and 
Families for computer-matching to indigenous status. 
This was successful in 94.1% of cases, and the data were 
transferred to the investigators linked to the study identifi er. 
Of those cases with a successful match, 59.7% of patients 
were neither indigenous nor Torres Strait Islander, 39.7% 
were Aboriginal, 0.1% were Torres Strait Islander, and 
0.6% were both Aboriginal and Torres Strait Islander. The 
suburb of patient’s address for each specimen was linked to 
2006 Statistical Local Area (SLA), the Australian Bureau 
of Statistics’ general purpose base spatial unit, with 82 of 
96 NT SLAs represented (11).
After testing, a small number of specimens were 
redistributed by region, following manual review of suburb 
of address linkage to SLA. The SLA code was also linked 
to the 11 statistical subdivisions and 7 health districts in the 
NT. Three study regions were defi ned, displayed in Figure 1, 
consisting of Urban Darwin; Rural Top End (Darwin Rural, 
East Arnhem, and Katherine districts); and Central Australia 
(Alice Springs Urban, Alice Springs Rural, and Barkly 
districts). SLA codes were then linked to the Australian 
Bureau of Statistics’ Socio-Economic Indexes for Area 
(SEIFA) (12). These measures use information from census 
data relating to material and social resources and ability 
to participate in society to obtain a broad level of relative 
socioeconomic status for each SLA. For calculation of attack 
rates by quintile, the SEIFA index of relative disadvantage 
was used, while for regression analysis, the SEIFA index of 
relative advantage and disadvantage was preferred, as this 
index does not incorporate indigenous status.
Laboratory Methods
Antibody responses to pandemic (H1N1) 2009 
infl uenza were assessed at the World Health Organization 
Collaborating Centre for Reference and Research on 
Infl uenza in North Melbourne, Victoria, Australia. 
Reactivity of serum against pandemic (H1N1) 2009 
infl uenza was measured in 2140 serum samples by 
using hemagglutination inhibition (HI). Egg-grown A/
California/7/2009 virus was purifi ed by sucrose gradient, 
concentrated, and inactivated with β-propiolactone to 
create an infl uenza zonal pool preparation (a gift from CSL 
Ltd., Parkville, Victoria, Australia). Serum samples were 
pretreated with 1:4 vol/vol receptor-destroying enzyme II 
(Deka Seiken Co. Ltd., Tokyo, Japan) at 37°C for 16 h, 
then enzyme was inactivated by the addition of an equal 
volume of 54.4 mmol/L trisodium citrate (Ajax Chemicals, 
Taren Point, New South Wales, Australia) and incubated at 
56°C for 30 min. A total of 25 μL (4 hemagglutinin units) 
infl uenza zonal pool preparation A/California/7/2009 virus 
or 25 μL phosphate-buffered saline (“no virus” control) 
was incubated at room temperature with an equal volume 
of receptor-destroying enzyme–treated serum. Serum 
specimens were titrated in 2-fold dilutions in phosphate-
buffered saline from 1:10 to 1:1280. After a 1-h incubation, 
25 μL of 1% vol/vol turkey erythrocytes was added to each 
well. HI was read after 30 min. Any samples that bound 
the erythrocytes in the absence of virus were adsorbed with 
erythrocytes for 1 hour and reassayed. Six samples bound 
erythrocytes in the absence of virus and were excluded 
from analysis. Titers were expressed as the reciprocal of 
the highest dilution of serum at which hemagglutination 
was prevented.
A panel of control and serum samples were run 
in addition to the test serum samples for all assays. The 
control panel comprised paired ferret serum samples pre- 
and postinfection with pandemic (H1N1) 2009; seasonal 
infl ueza A (H1N1), A (H3N2), or B viruses; and paired 
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human plasma and serum samples from donors, collected 
before April 2009 or after known infection with pandemic 
(H1N1) 2009 or vaccination with the Australian monovalent 
pandemic (H1N1) 2009 vaccine.
Study Population
We aimed to estimate the proportion of persons with 
serologic immunity in each of 12 groups in the post-
pandemic sample, consisting of 4 age groups (<14, 15–
34, 35–54, and >55 y) within each of the 3 study regions 
described. In the postpandemic group, we calculated a 
required sample size of 195 specimens per group (for a 
total of 2,340 specimens) on the basis of an estimate of 
15% immunity with a 95% confi dence interval (CI) of 
10%–20%.
In the baseline group, we aimed to provide an age-
specifi c, NT-wide estimate of preexisting immunity and 
calculated a single sample size for each of the same 4 
age groups described. We did not stratify by region and 
assumed increasing prepandemic immunity with age (2% 
in those <14 y, 5% in those 15–54 y, and 15% in those 
>55 y).
Samples were chosen at random from each stratum 
and checked for representativeness of the NT population 
by gender and region before testing. Data on indigenous 
status were obtained from Information Services only after 
fi nal selection of specimens.
Analytic Methods
For all analyses, immunity was defi ned as an HI titer 
≥40, consistent with published data (13) and the observation 
that titers of this order develop in 90% of persons <21 days 
of illness (14). Attack rates were calculated as the difference 
in proportion immune between the September category and 
the total baseline group, except for age-specifi c attack rates 
where the age-specifi c baseline proportion was used as 
the reference. All attack rate calculations were population 
standardized, with weights calculated separately for pre- 
and postpandemic samples, based on the demographic 
characteristics of the 2009 NT population by age-group, 
indigenous status, and study region. Regression models and 
proportions immune are displayed unweighted. Statistical 
analysis was performed with Stata version 11.0 (StataCorp 
LP, College Station, TX, USA).
Ethical Approval
We obtained ethical approval from the Menzies School 
of Health Research Human Research Ethics Committee and 
the Central Australia Human Research Ethics Committee. 
We continued to liaise with the Aboriginal and Torres 
Strait Islander subcommittees of both ethics committees 
throughout the study.
Results
Baseline Immunity
A total of 445 specimens taken January 10–May 29 
were selected from 10,575 available serum tubes (Table 1). 
Within each age group sampled, the baseline sample was 
representative of the 2009 NT population (15) by gender, 
indigenous status, and study region, except that higher 
proportions of indigenous Australians were seen in the 
2 older age brackets. There was no tendency toward an 
increase in the proportion of specimens with protective 
immunity over the 5 months from which baseline specimens 
were taken (p = 0.79, by χ2 test for trend).
A total of 34 of 445 baseline specimens (7.6%, 95% 
CI 5.2%–10.1%) had HI titers >40. Multivariate logistic 
regression revealed no difference in baseline immunity 
by gender, indigenous status, study region, or index of 
socioeconomic disadvantage (p>0.05), with increasing 
age in years the only signifi cant independent predictor 
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Figure 1. Health districts, by study region, in a study of differential 
effects of pandemic (H1N1) 2009 on remote and indigenous groups, 
Northern Territory, Australia, September 2009. Black, Urban Darwin; 
white, Rural Top End; gray, Central Australia. Inset: Location of the 
Northern Territory in Australia.
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of prepandemic immunity (p = 0.003). Although not 
statistically signifi cant on the regression model, the 
proportion of specimens with titers >40 appeared higher 
in Central Australia (14.0%) than Urban Darwin and Rural 
Top End (5.6%). Immunity was nevertheless evenly spread 
geographically within these regions.
Postpandemic Immunity
A total of 1,689 specimens collected September 3–30, 
2009, were selected from 3,228 available. Because of 
insuffi cient numbers of specimens, the required sample 
size was not achieved in 5 of 12 postpandemic groups. The 
September samples were representative of the 2009 NT 
population by gender but again included higher proportions 
of specimens from indigenous Australians in the older 
age brackets. An HI titer >40 was seen in 329 specimens 
(19.5%, 95% CI 17.6%–21.4%), with proportions by study 
group shown in Table 2, geometric mean titers in Figure 
2, and reverse cumulative distributions in Figure 3. There 
was a nonsignifi cant trend toward a decreasing proportion 
of specimens with protective immunity over the 5 weeks 
from which the September specimens were taken (p = 0.20, 
by χ2 test for trend).
Table 3 shows the results of multivariate logistic 
regression analysis for the 1,592 postpandemic specimens 
for which the indigenous status of patients was known. No 
association was detected between immunity and gender, 
socioeconomic status, or study region. However, younger 
age and indigenous status were independently associated 
with immunity. A measure of remoteness was examined 
as a possible exposure variable, but colinearity with region 
meant that it was not a useful predictor variable and 
therefore was not included in regression analysis (16).
The proportion immune in September was 
geographically heterogeneous across the 3 study regions 
(p<0.001, by χ2 test). The same pattern was seen for 
Statistical Subdivisions (p<0.001, by χ2 test), with 
proportionate immunity ranging from 7.5% to 42.9%, as 
illustrated in Figure 4. The picture of heterogeneity was also 
seen for the indigenous population considered separately. 
However, the prevalence of postpandemic immunity was 
more homogeneous for the nonindigenous population 
considered by either geographic classifi cation and for 
urban Darwin considered separately. Figure 5 demonstrates 
that while postpandemic levels of immunity were relatively 
homogeneous by SLA in less disadvantaged, generally 
urban areas, comparatively disadvantaged areas had more 
variable levels of immunity.
Attack Rates
As shown in Table 4, attack rates by age group were 
markedly higher in younger groups, reaching approximately 
1 in 3 among children <14 years of age. Indigenous 
Australians were also disproportionately affected, with 
attack rates of ≈1 in 4, which were 1.85-fold higher than 
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Table 1. Demographic characteristics of patients in a study of 
differential effects of pandemic (H1N1) 2009 on remote and 
indigenous groups, Northern Territory, Australia, 2009 
Characteristic
No.
patients
Female, 
%
Indigenous,
%
Baseline, age, y 
 <14 37 54.1 51.4
 15–34 91 65.9 43.5
 35–54 92 54.4 33.7
 >55 225 44.9 30.3
 Total 445 51.9 35.5
September, Urban Darwin, age, y 
 <14 60 53.3 14.0
 15–34 194 62.9 13.5
 35–54 202 55.5 9.6
 >55 209 48.3 6.7
 Total 665 55.2 10.2
September, Rural Top End, age, y 
 <14 25 36.0 44.0
 15–34 190 60.5 71.4
 35–54 183 47.5 60.8
 >55 190 46.8 42.5
 Total 588 51.0 57.8
September, Central Australia, age, y 
 <14 13 46.2 61.5
 15–34 84 57.1 82.7
 35–54 189 63.5 63.2
 >55 150 51.3 54.9
 Total 436 57.6 64.1
Table 2. Specimens with titers >40 in a study of differential 
effects of pandemic (H1N1) 2009 on remote and indigenous 
groups, Northern Territory, Australia, September 2009* 
Population group 
No. positive/ 
no. tested 
% Titers >40
(95% CI) 
Baseline, age, y 
 <14 0/37 0
 15–34 4/91 4.4 (0.1–8.6) 
 35–54 8/92 8.7 (2.9–14.5) 
 >55 22/225 9.8 (5.9–13.7) 
Urban Darwin, age, y 
 <14 22/60 36.7 (24.3–49.0) 
 15–34 34/194 17.5 (12.2–22.9) 
 35–54 23/202 11.4 (7.0–15.8) 
 >55 20/209 9.6 (5.6–13.6) 
Rural Top End, age, y 
 <14 5/25 20.0 (4.0–36.0) 
 15–34 46/190 24.2 (18.1–30.3) 
 35–54 31/183 16.9 (11.5–22.4) 
 >55 35/190 18.4 (12.9–24.0) 
Central Australia, age, y 
 <14 7/13 53.9 (25.6–82.1) 
 15–34 23/84 27.4 (17.8–37.0) 
 35–54 50/189 26.5 (20.1–32.8) 
 >55 33/150 22.0 (15.3–28.7) 
*CI, confidence interval. 
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those seen in nonindigenous Australians. No differences in 
attack rates were seen by gender, region, or socioeconomic 
quintile. Given these attack rates, we estimate that 15,600 
(95% CI 10,900–20,300) of 67,820 indigenous and 19,500 
(95% CI 12,700–26,300) of 157,028 nonindigenous 
persons in the NT acquired pandemic infl uenza during 
May–September 2009.
Discussion
Our study is an outpatient-based serologic survey of 
the impact of pandemic infl uenza over a large geographic 
region. Because of our broad sampling base, we have been 
able to estimate attack rates across the NT population 
and to assess the differential impact of the virus on the 
indigenous population. We calculated a population attack 
rate of ≈15% but found marked differences in patterns 
of exposure by indigenous status, geographic location, 
and age. Younger age groups and indigenous Australians 
were disproportionately affected, with striking geographic 
variations seen.
Baseline immunity could be overestimated if 
undetected virus circulation was occurring during our 
prepandemic period. We believe this is unlikely, as there 
was no trend toward increasing immunity in samples 
taken at a later date, no child had a baseline titer >10, and 
the fi rst confi rmed case was not detected in the NT until 
May 29 (17). Similarly, our September sample could have 
underestimated true postpandemic immunity caused by 
ongoing infection during this month. However, emergency 
department presentations of infl uenza-like illness had 
returned to baseline by this time, and there were few 
laboratory-confi rmed cases during this period. Similarly, 
no increase in immunity was observed during September 
in our study. Because the national pandemic vaccination 
program in Australia commenced in NT on September 30, 
testing of specimens before this date would be unaffected 
by antibodies produced by vaccination (18).
Although we attempted to ensure that our sample was 
demographically representative of the NT population, the 
prevalence of risk factors for infl uenza infection may be 
different in our sample from that of the general population. 
In particular, chronic disease and pregnancy may have been 
overrepresented among patients presenting for outpatient 
pathologic analysis. However, because clinical data, 
including indication for testing, were not available, the 
strength of this possible effect cannot be assessed.
We found a prevalence of preexisting immunity of 
3.6% in those born after 1980 and of 0% in children. In 
those born before 1950, the level of pre-existing immunity 
was 13.7%, which is lower than data from North America 
(19,20). This may refl ect regional differences or be the result 
of the 1976 mass-vaccination campaign against swine-
origin H1N1 virus because seasonal infl uenza vaccination 
does not produce protective titers against the pandemic 
(H1N1) 2009 virus. Despite this fi nding, serologic data 
from a population in China with low seasonal vaccine 
coverage found lower levels of preexisting immunity (21), 
although comparable levels of preexisting immunity were 
seen in Singapore (22).
Our fi ndings of a postpandemic proportion immune 
rate of 19.5%, attack rate of 14.9%, and the association 
with younger age are consistent with other published 
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Figure 2. Unadjusted geometric mean antibody 
titers by age group (A), sex (B), indigenous 
status (C), SEIFA index (D), and study region 
(E) in a study of differential effects of pandemic 
(H1N1) 2009 on remote and indigenous groups, 
Northern Territory, Australia, September 2009. 
Red, prepandemic titer; blue, postpandemic 
titer. Bars indicate range. SEIFA, Australian 
Bureau of Statistics’ Socio-Economic Indexs 
for Area.
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data (14,22), although the difference in post-pandemic 
immunity in the Australian indigenous population has not 
been reported. Our overall attack rate was notably higher 
than the estimated clinical attack rate of 7.2% extrapolated 
from surveillance data (23). Moreover, the incidence rate 
ratio between indigenous and nonindigenous populations 
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Figure 3. Reverse cumulative distributions by age group in a study of differential effects of pandemic (H1N1) 2009 on remote and 
indigenous groups, Northern Territory, Australia, September 2009, showing percentage of population with titer at or above each value. A) 
<15 years of age; B) 15–34 years of age; C) 35–54 years of age; D) >55 years of age. Red, prepandemic titer; blue, postpandemic titer.
Table 3. Multivariate logistic regression for exposures associated with titer >40 in a study of differential effects of pandemic (H1N1) 
2009 on remote and indigenous groups, Northern Territory, Australia, September 2009 
Characteristic Odds ratio (95% confidence interval) p value 
Female sex  1.06 (0.82–1.37) 0.65
Aboriginal and Torres Strait Islander 2.32 (1.63–3.31) <0.001 
Age, y <0.001 
 >55 Reference 
 35–54 1.05 (0.76–1.45) 
 15–34 1.28 (0.91–1.79) 
 <14 2.98 (1.80–4.92) 
Region 0.05
 Urban Darwin Reference 
 Rural Top End 0.83 (0.56–1.23) 
 Central Australia 1.23 (0.80–1.90) 
Socioeconomic quintile* 0.43
 5 (least disadvantaged) Reference 
 4 0.91 (0.55–1.51) 
 3 1.16 (0.73–1.86) 
 2 1.41 (0.84–2.36) 
 1 (most disadvantaged) 1.21 (0.70–2.12) 
*Australian Bureau of Statistics’ Socio-Economic Indexes for Area index of relative socioeconomic advantage and disadvantage. 
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based on the number of laboratory-confi rmed cases was 
4.9, notably greater than our 2-fold ratio. However, the 
ratio in serologic attack rates between Central Australia 
and the Top End was ≈1.5 and consistent with the 
ratio from laboratory-confi rmed cases (23). Data from 
notifi cations and hospitalizations in the Top End indicate 
that the prevalence of risk factors in patients admitted with 
pandemic infl uenza was similar between indigenous and 
nonindigenous patients (24), suggesting that the increased 
frequency of admissions in indigenous persons was because 
of the greater prevalence of risk factors for severe disease.
Australian indigenous populations have more 
respiratory infections than nonindigenous groups (25), 
and the higher pandemic attack rate in this group is also 
consistent with their overrepresentation in admissions 
to intensive care units (26). North American indigenous 
persons also have a greatly increased risk for hospitalization 
and death from pandemic (H1N1) 2009 infl uenza compared 
with their nonindigenous counterparts, particularly at 
extremes of age (27). However, Australia has among the 
greatest differences in rates of hospitalization and mortality 
between indigenous and nonindigenous populations in the 
Americas and Pacifi c regions (28). For this reason, the 
NT Centre for Disease Control has identifi ed this group 
as a particular focus of the univalent pandemic infl uenza 
vaccination program, achieving coverage of 24% overall 
and 41% in the indigenous population.
We used the Australian Bureau of Statistics 
SEIFA index as our measure of relative socioeconomic 
disadvantage (12). By this measure, the most disadvantaged 
quintile appeared to have higher rates of infection. 
However, this fi nding was not borne out by multivariate 
analysis, suggesting confounding by other variables, 
particularly indigenous status and remoteness, which are 
highly correlated in NT. Moreover, accurate estimates of 
socioeconomic disadvantage are notoriously diffi cult to 
attain (29) and, when measured by area, are at best at an 
average level of deprivation.
We observed marked differences in the postpandemic 
proportion immune between Statistical Subdivisions, with 
the degree of heterogeneity being particularly prominent 
among indigenous and remote populations. This variability 
in infl uenza infections has been noted from surveillance 
data (30) and serologic survey data (14). Although many 
Aboriginal communities in the NT are remote and isolated, 
a large proportion of persons from remote communities 
demonstrate intercommunity mobility (31). The Aboriginal 
population of the NT is known to have high rates of chronic 
diseases, including conditions identifi ed as increasing 
susceptibility to infl uenza (4,32), such as poor housing 
(33) and sanitation (34). These factors, in particular 
overcrowding, are likely to facilitate transmission of 
infl uenza once the disease is present within a community.
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Figure 4. Postpandemic proportion immune by statistical sub-
division in a study of differential effects of pandemic (H1N1) 2009 
on remote and indigenous groups, Northern Territory, Australia, 
September 2009. Inset represents Urban Darwin. 
Figure 5. Postpandemic proportion of Statistical Local Area (SLA) 
demonstrating titers >40 by Socio-economic Index for Area (SEIFA) 
of relative socioeconomic disadvantage. Gray circles, Urban 
Darwin; black circles, Rural Top End and Central Australia. Circle 
size proportional to number of specimens in group. Lower score 
indicates greater degree of relative socioeconomic disadvantage. 
One SLA containing 1 observation with a proportion immune of 
100% is not displayed.
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Our results suggest that although some communities 
were severely affected, others may have been less 
affected by the pandemic because of their isolation. These 
communities are likely to be particularly susceptible to 
subsequent waves of infection because East Arnhem 
communities were particularly hard hit by pandemic 
(H1N1) 2009 in 2010, and Central Australia communities 
were relatively spared. Moreover, the fi rst cluster of 
laboratory-confi rmed cases since the fi rst pandemic wave 
occurred in June and July 2010 in the SLA with the 
lowest postpandemic proportional immunity of any SLA 
represented by >20 specimens (2/38, 5.4%).
Our serosurvey indicates that the full effect of 
the infl uenza pandemic on the NT may have been 
underestimated and highlights the differential impact of 
the virus on vulnerable groups, including children and 
indigenous populations. Our fi ndings show similarities 
to other published data, but the results are more likely 
to be applicable to remote-living and ethnically diverse 
populations. Given that in all groups, the majority of the 
population is likely to remain susceptible to the virus 
following the pandemic, vaccination campaigns and public 
health responses are essential and should focus on high-
risk groups, which requires respectful engagement with 
communities.
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